312 related articles for article (PubMed ID: 26055302)
1. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
Dorrance AM; Neviani P; Ferenchak GJ; Huang X; Nicolet D; Maharry KS; Ozer HG; Hoellarbauer P; Khalife J; Hill EB; Yadav M; Bolon BN; Lee RJ; Lee LJ; Croce CM; Garzon R; Caligiuri MA; Bloomfield CD; Marcucci G
Leukemia; 2015 Nov; 29(11):2143-53. PubMed ID: 26055302
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion.
Si X; Zhang X; Hao X; Li Y; Chen Z; Ding Y; Shi H; Bai J; Gao Y; Cheng T; Yang FC; Zhou Y
Oncotarget; 2016 Nov; 7(47):78095-78109. PubMed ID: 27801668
[TBL] [Abstract][Full Text] [Related]
4. Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
Bill M; Papaioannou D; Karunasiri M; Kohlschmidt J; Pepe F; Walker CJ; Walker AE; Brannan Z; Pathmanathan A; Zhang X; Mrózek K; LaRocco A; Volinia S; Bloomfield CD; Garzon R; Dorrance AM
Leukemia; 2019 Sep; 33(9):2169-2182. PubMed ID: 30858548
[TBL] [Abstract][Full Text] [Related]
5. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
6. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1.
Zhang Y; Zhou SY; Yan HZ; Xu DD; Chen HX; Wang XY; Wang X; Liu YT; Zhang L; Wang S; Zhou PJ; Fu WY; Ruan BB; Ma DL; Wang Y; Liu QY; Ren Z; Liu Z; Zhang R; Wang YF
Sci Rep; 2016 Feb; 6():19995. PubMed ID: 26847520
[TBL] [Abstract][Full Text] [Related]
7. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
Wong P; Iwasaki M; Somervaille TC; Ficara F; Carico C; Arnold C; Chen CZ; Cleary ML
Cancer Res; 2010 May; 70(9):3833-42. PubMed ID: 20406979
[TBL] [Abstract][Full Text] [Related]
8. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.
Huang X; Schwind S; Santhanam R; Eisfeld AK; Chiang CL; Lankenau M; Yu B; Hoellerbauer P; Jin Y; Tarighat SS; Khalife J; Walker A; Perrotti D; Bloomfield CD; Wang H; Lee RJ; Lee LJ; Marcucci G
Oncotarget; 2016 Sep; 7(37):59273-59286. PubMed ID: 27517749
[TBL] [Abstract][Full Text] [Related]
9. DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.
Ye S; Xiong F; He X; Yuan Y; Li D; Ye D; Shi L; Lin Z; Zhao M; Feng S; Zhou B; Weng H; Hong L; Ye H; Gao S
Theranostics; 2023; 13(1):77-94. PubMed ID: 36593968
[No Abstract] [Full Text] [Related]
10. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
[TBL] [Abstract][Full Text] [Related]
11. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
12. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.
Zhang L; Nguyen LXT; Chen YC; Wu D; Cook GJ; Hoang DH; Brewer CJ; He X; Dong H; Li S; Li M; Zhao D; Qi J; Hua WK; Cai Q; Carnahan E; Chen W; Wu X; Swiderski P; Rockne RC; Kortylewski M; Li L; Zhang B; Marcucci G; Kuo YH
Nat Commun; 2021 Oct; 12(1):6154. PubMed ID: 34686664
[TBL] [Abstract][Full Text] [Related]
13. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
[TBL] [Abstract][Full Text] [Related]
14. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis.
Jung N; Dai B; Gentles AJ; Majeti R; Feinberg AP
Nat Commun; 2015 Oct; 6():8489. PubMed ID: 26444494
[TBL] [Abstract][Full Text] [Related]
15. miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
Peng D; Wang H; Li L; Ma X; Chen Y; Zhou H; Luo Y; Xiao Y; Liu L
Leukemia; 2018 May; 32(5):1180-1188. PubMed ID: 29479064
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
17. [New approaches to target leukemia stem cells].
Takenaka K; Akashi K
Nihon Rinsho; 2014 Jun; 72(6):1018-25. PubMed ID: 25016798
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
19. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW
Cell Stem Cell; 2014 Dec; 15(6):775-90. PubMed ID: 25479751
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
